Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
2 findings from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) probably leads to higher mental state: 1. No clinically important improvement ‐ as measured… compared with ANY DOSE ‐ short term (moderate certainty).
2 findings from 1 review
Leaving the study early · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower leaving the study early ‐ any reason compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Behaviour: deterioration of behaviour (categorised as reason to leave early) · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) may leads to higher behaviour: deterioration of behaviour (categorised as reason to… compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (low certainty).
1 finding from 1 review
Adverse effects: unspecified extrapyramidal symptoms · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: unspecified extrapyramidal symptoms compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Adverse event: Death · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in adverse event: death compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to higher global state: no clinically important improvement ‐ medium term compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · schizophrenia
1 finding from 1 review